NSRX.US Nasus Pharma Ltd.
- Market cap
- USD 33.6M
- P/E
- -
- P/B
- 3.06x
- ROE
- -162.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NSRX.US undervalued?
Graham numberThe Graham number of Nasus Pharma Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nasus Pharma Ltd. fundamental analysis
No fundamental analysis for Nasus Pharma Ltd. yet.
Nasus Pharma Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdos…
Full company profileNasus Pharma Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nasus Pharma Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -2.04M | -1.15M | -1.08M | -4.90M | -18.1M |
| EBITDA | -2.13M | -956K | -1.52M | -4.90M | - |
| Net Income | -1.71M | -1.05M | -1.53M | -5.86M | -17.8M |
| EPS | -0.19 | -0.12 | -0.17 | -0.73 | -1.61 |
| Balance Sheet | |||||
| Total Assets | 417K | 444K | 717K | 5.00M | 12.4M |
| Total Liabilities | 3.20M | 4.24M | 3.93M | 2.24M | 1.45M |
| Shareholders' Equity | -2.79M | -3.80M | -3.21M | 2.77M | 11.0M |
| Cash & Short-term Investments | 154K | 193K | 284K | 4.29M | 11.8M |
| Total Debt | 1.57M | 2.46M | 1.80M | 118K | 103K |
| Cash Flow | |||||
| Operating Cash Flow | -1.21M | -1.03M | -665K | -4.92M | -3.98M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 14.0K | 2.65K |
| Free Cash Flow | -1.21M | -1.03M | -665K | -4.93M | -3.99M |
| Ratios | |||||
| ROE | - | - | - | -211.6% | -162.1% |
| ROA | -410.3% | -236.7% | -213.7% | -117.0% | -143.2% |
| Debt to Equity | - | - | - | 0.04x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nasus Pharma Ltd. dividends
Nasus Pharma Ltd. has not paid dividends in the last 4 fiscal years.
Who owns Nasus Pharma Ltd.
- Insiders 49.15%
- Institutions 18.38%
- Public & others 32.47%
- Shares outstanding 11.7M
- Free float 5.46M
Nasus Pharma Ltd. company profile
- Company name
- Nasus Pharma Ltd.
- Ticker
- NSRX.US
- ISIN
- IL0012181553
- Exchange
- USA Stocks
- Listed since
- Aug 13, 2025
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7
- Fiscal year end
- December
- Address
- Yigal Alon 65, Tel Aviv-Yafo, Israel, 6744317
- Phone
- 972 3 573 6632
- Website
- nasuspharma.com
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd. management
5- Mr. Ehud Moshe Gilboa MBACo-Founder & Executive Chairman · born 1966
- Dr. Dalia Megiddo M.B.A., M.D., Ph.D.Co-Founder, Director, Chief Medical Officer & Chief Development Officer? · born 1952
- Mr. Brendan P. O'GradyCEO & Director · born 1967
- Mr. Oren ElmaliachInterim Chief Financial Officer · born 1984
- Dr. Galia Temtsin Kryaz Ph.D.Director of CMC & Product Development · born 1967